Drugs / Adjuvanted RSVPreF3 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07092865 | Aug 2025 → Jan 2027 expected | respiratory syncytial virus infectious disease | GlaxoSmithKline | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | GlaxoSmithKline | Results GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced new effectiveness data for its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | GlaxoSmithKline | GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adjuvanted RSVPreF3 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07092865 ↗ |
| Modality | Vaccine | “Adjuvanted RSVPreF3 vaccine” NCT07092865 ↗ |
| Route | Intramuscular | “1 dose of adjuvanted RSVPreF3 vaccine administered intramuscularly at Visit 1 (Day 1).” NCT07092865 ↗ |